• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bivalirudin Use for Primary Percutaneous Coronary Intervention on Long-Term Mortality.

作者信息

Caturano Alfredo

机构信息

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli," Naples, IT.

出版信息

J Cardiovasc Pharmacol. 2021 Jul 1;78(1):e3-e4. doi: 10.1097/FJC.0000000000001052.

DOI:10.1097/FJC.0000000000001052
PMID:33958548
Abstract
摘要

相似文献

1
Bivalirudin Use for Primary Percutaneous Coronary Intervention on Long-Term Mortality.比伐卢定用于直接经皮冠状动脉介入治疗对长期死亡率的影响
J Cardiovasc Pharmacol. 2021 Jul 1;78(1):e3-e4. doi: 10.1097/FJC.0000000000001052.
2
Postprocedure bivalirudin infusion for primary percutaneous coronary intervention.
Catheter Cardiovasc Interv. 2019 Nov 15;94(6):900-901. doi: 10.1002/ccd.28377. Epub 2019 Jun 26.
3
Bivalirudin in acute coronary syndromes and percutaneous coronary intervention: should we use it?比伐卢定在急性冠脉综合征和经皮冠状动脉介入治疗中的应用：我们应该使用它吗？
Heart Lung Circ. 2013 Oct;22(10):793-800. doi: 10.1016/j.hlc.2013.05.636. Epub 2013 Jul 31.
4
The effects of bivalirudin vs heparin on short-term outcomes in patients undergoing percutaneous coronary intervention.比伐芦定与肝素对接受经皮冠状动脉介入治疗患者短期预后的影响。
Int J Cardiol. 2016 Jul 1;214:270-4. doi: 10.1016/j.ijcard.2016.03.214. Epub 2016 Apr 3.
5
Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.在ST段抬高型心肌梗死患者的直接经皮冠状动脉介入治疗中肝素与比伐卢定单药治疗的比较
Ann Pharmacother. 2016 Feb;50(2):141-51. doi: 10.1177/1060028015618206. Epub 2015 Dec 17.
6
Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified.
EuroIntervention. 2017 Mar 20;12(16):1930-1932. doi: 10.4244/EIJV12I16A315.
7
Effectiveness and Safety of Bivalirudin During Percutaneous Coronary Intervention in Acute Coronary Syndrome in the Real World: CARTAGOMAX Study.
J Cardiovasc Pharmacol. 2016 Sep;68(3):248-56. doi: 10.1097/FJC.0000000000000411.
8
Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials.ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后早期支架血栓形成与死亡率：2 项随机临床试验的患者水平分析。
Circ Cardiovasc Interv. 2016 May;9(5):e003272. doi: 10.1161/CIRCINTERVENTIONS.115.003272.
9
Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.与肝素和糖蛋白IIb/IIIA抑制剂相比，接受比伐卢定经皮冠状动脉介入治疗的糖尿病患者的短期和长期结局：一项随机试验的荟萃分析。
Catheter Cardiovasc Interv. 2015 Sep;86(3):364-75. doi: 10.1002/ccd.25952. Epub 2015 Apr 24.
10
Bivalirudin Across the Atlantic.
JACC Cardiovasc Interv. 2017 Jun 12;10(11):1112-1114. doi: 10.1016/j.jcin.2017.04.004. Epub 2017 May 17.

引用本文的文献

1
One-Year Safety and Effectiveness of Bivalirudin Heparin in Patients Undergoing Elective Percutaneous Coronary Intervention.比伐卢定与肝素用于择期经皮冠状动脉介入治疗患者的一年安全性和有效性
Rev Cardiovasc Med. 2023 Jul 31;24(8):218. doi: 10.31083/j.rcm2408218. eCollection 2023 Aug.